HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug evaluation: bevirimat--HIV Gag protein and viral maturation inhibitor.

Abstract
Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.
AuthorsZelalem Temesgen, Judith E Feinberg
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 7 Issue 8 Pg. 759-65 (Aug 2006) ISSN: 1472-4472 [Print] England
PMID16955688 (Publication Type: Journal Article, Review)
Chemical References
  • Gene Products, gag
  • Succinates
  • Triterpenes
  • bevirimat
Topics
  • Animals
  • Clinical Trials, Phase II as Topic
  • Drug Evaluation, Preclinical
  • Gene Products, gag (antagonists & inhibitors)
  • HIV Infections (drug therapy, metabolism)
  • HIV-1 (metabolism)
  • Humans
  • Succinates (adverse effects, pharmacokinetics, pharmacology, therapeutic use)
  • Triterpenes (adverse effects, pharmacokinetics, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: